Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NASDAQ:EWTX NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$81.03-0.7%$44.05$4.77▼$82.13$6.12B0.591.07 million shs578,505 shsAXSMAxsome Therapeutics$121.28-0.4%$108.21$75.56▼$139.13$6.05B0.54562,275 shs351,676 shsEWTXEdgewise Therapeutics$14.35-2.0%$13.78$10.60▼$38.12$1.51B0.26732,662 shs670,556 shsRNAAvidity Biosciences$46.58-4.1%$37.39$21.51▼$56.00$5.99B0.993.38 million shs1.44 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+4.85%+12.64%+1,176.06%+537.53%AXSMAxsome Therapeutics0.00%+2.34%+17.72%+12.65%+36.48%EWTXEdgewise Therapeutics0.00%-3.37%+0.28%-2.31%-23.47%RNAAvidity Biosciences0.00%+0.50%+29.68%+40.43%+5.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax2.3868 of 5 stars3.63.00.00.02.20.80.6AXSMAxsome Therapeutics4.7903 of 5 stars4.51.00.04.54.04.20.6EWTXEdgewise Therapeutics2.2955 of 5 stars3.52.00.00.02.82.50.0RNAAvidity Biosciences3.0542 of 5 stars4.52.00.00.04.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3313.95% UpsideAXSMAxsome Therapeutics 3.07Buy$178.0046.77% UpsideEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55182.55% UpsideRNAAvidity Biosciences 3.06Buy$67.0043.84% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, RNA, AXSM, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.008/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $49.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$59.00 ➝ $62.008/8/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$150.007/30/2025EWTXEdgewise TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$46.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$74.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAXSMAxsome Therapeutics$385.69M15.69N/AN/A$1.18 per share102.78EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ARNAAvidity Biosciences$10.90M549.77N/AN/A$11.94 per share3.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAXSMAxsome Therapeutics-$287.22M-$5.07N/A43.01N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest EWTX, RNA, AXSM, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AXSMAxsome Therapeutics1.661.571.51EWTXEdgewise TherapeuticsN/A28.8728.87RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%EWTXEdgewise TherapeuticsN/ARNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics22.40%EWTXEdgewise Therapeutics23.20%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableEWTX, RNA, AXSM, and ABVX HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Purchases 42,873 Shares of Avidity Biosciences, Inc. $RNAAugust 31 at 7:14 AM | marketbeat.comSiren L.L.C. Decreases Holdings in Avidity Biosciences, Inc. $RNAAugust 31 at 6:29 AM | marketbeat.comRafferty Asset Management LLC Sells 32,167 Shares of Avidity Biosciences, Inc. $RNAAugust 31 at 5:22 AM | marketbeat.comInsider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 25,000 Shares of StockAugust 30 at 7:18 AM | insidertrades.comInvesco Ltd. Purchases 193,376 Shares of Avidity Biosciences, Inc. $RNAAugust 28, 2025 | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferencesAugust 27, 2025 | prnewswire.comBI Asset Management Fondsmaeglerselskab A S Sells 52,463 Shares of Avidity Biosciences, Inc. $RNAAugust 27, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 295,275 Shares of Avidity Biosciences, Inc. $RNAAugust 26, 2025 | marketbeat.com771,158 Shares in Avidity Biosciences, Inc. $RNA Acquired by T. Rowe Price Investment Management Inc.August 26, 2025 | marketbeat.comRNA Stock Moves More Than 30% in a Week: What's Driving This Rally?August 25, 2025 | zacks.comNuveen LLC Invests $12.73 Million in Avidity Biosciences, Inc. $RNAAugust 24, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in StockAugust 23, 2025 | insidertrades.comCandriam S.C.A. Increases Stock Position in Avidity Biosciences, Inc. $RNAAugust 23, 2025 | marketbeat.comWellington Management Group LLP Has $285.89 Million Stock Holdings in Avidity Biosciences, Inc. $RNAAugust 22, 2025 | marketbeat.comAberdeen Group plc Increases Holdings in Avidity Biosciences, Inc. $RNAAugust 22, 2025 | marketbeat.comAvidity Biosciences, Inc. $RNA Shares Sold by Swiss National BankAugust 22, 2025 | marketbeat.comAvidity Biosciences Sees Unusually High Options Volume (NASDAQ:RNA)August 21, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Down 4.2% on Insider SellingAugust 20, 2025 | marketbeat.comAvidity Biosciences, Inc. $RNA Holdings Cut by Vanguard Group Inc.August 19, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Citigroup Inc.August 18, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Deutsche Bank AGAugust 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDisney’s Iger-Led Turnaround Gains TractionBy Thomas Hughes | August 6, 20252 Powerful Forces Now Back Intel's TurnaroundBy Jeffrey Neal Johnson | August 20, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsBy Jeffrey Neal Johnson | August 15, 2025EWTX, RNA, AXSM, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$81.03 -0.61 (-0.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$81.39 +0.36 (+0.44%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$121.28 -0.47 (-0.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$121.25 -0.03 (-0.02%) As of 08/29/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Edgewise Therapeutics NASDAQ:EWTX$14.35 -0.30 (-2.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.36 +0.01 (+0.07%) As of 08/29/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Avidity Biosciences NASDAQ:RNA$46.58 -2.00 (-4.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$46.50 -0.08 (-0.17%) As of 08/29/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
